Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Amneal Pharmaceuticals, Inc.

ALPHAEON is a healthcare company that develops and provides aesthetic products and medical devices for healthcare professionals and patients

ALPHAEON

Amneal Pharmaceuticals develops and provides generic and specialty pharmaceuticals, focusing on essential medicines.

Metric
Company Name	Amneal Pharmaceuticals, Inc.	ALPHAEON
Symbol	AMRX
MSH ID	COM:AMNEAL	COM:ALPHAEON
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Medical Devices and Aesthetics
Country	US	US
Stage
Employee Count	7.85K
Website	amneal.com	alphaeon.com
LinkedIn
Founders

Metric
Market Cap	2.19B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.39B
Revenue (LTM)
Revenue (NTM)
Gross Profit	820.57M
EBITDA	417.96M
Operating Income	204.37M
Net Income	-83.99M
EPS	-0.48
Diluted EPS	-0.48
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.35
Operating Profit Margin	0.09
EBITDA Margin	0.17
Net Profit Margin	-0.04
Return on Equity	-0.76
Return on Assets	-0.03
Return on Capital Employed	0.08

COM:AMNEAL

Amneal Pharmaceuticals

Last Close

8.32

22/11 21:00

Market Cap

2.19B

Beta: -

Volume Today

749.52K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	151.43
P/B Ratio	5.54
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.05
EV Multiple	0.67

Metric
Days Sales Outstanding	105.93
Days Payables Outstanding	132.17
Days Inventory Outstanding	134.90
Operating Cycle	237.37
Cash Conversion Cycle	232.66
Asset Turnover	0.74

Metric
Operating Cash Flow	345.58M
Free Cash Flow	276.39M
Cash Flow to Debt	0.13
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield	0.08

Metric
Cash & Equivalents	91.54M
Accounts Receivable	126.29M
Inventory	581.38M
Goodwill	598.63M
Debt to Capitalization	1.03
Debt to Assets	0.76
Current Ratio	1.91
Quick Ratio	0.97

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.07
SG&A to Revenue